Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamrevlumab vs placebo in idiopathic pulmonary fibrosis (ZEPHYRUS-2)
CTR20221946Phase 3Terminated
- Sponsor
- Fapon Biopharma
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Pamrevlumab with Placebo (2 arms). Primary endpoint: Time to disease progression. Started Sep 2022; status: terminated.
02
Drugs
pamrevlumab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on CTR20221946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221946.